Heart Failure Clinical Trial

A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure

Summary

The purpose of this clinical study is to estimate the safety and radiation dosimetry of a single dose of LMI1195 in healthy subjects and heart failure patients undergoing positron emission tomography (PET)

View Eligibility Criteria

Eligibility Criteria

Cohort 1 Inclusion:

Healthy, age 18-40

Cohort 1 Exclusion:

Significant or chronic medical illness
Pregnant females
Smoking within one month of enrollment
Use of any prescription drugs within 4 weeks prior to dosing

Cohort 2 Inclusion:

30-70 year old subjects with a diagnosis of NYHA Class II-III heart failure
Ejection fraction less than or equal to 35%
Rest SPECT imaging within 90 days prior to enrollment

Cohort 2 Exclusion:

Significant or chronic medical illness
Pregnant females
Known history of arrhythmogenic disorder or rhythm disorder

Study is for people with:

Heart Failure

Phase:

Phase 1

Estimated Enrollment:

12

Study ID:

NCT00891241

Recruitment Status:

Completed

Sponsor:

Lantheus Medical Imaging

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Hartford Hospital
Hartford Connecticut, 06102, United States
Yale University Medical Center
New Haven Connecticut, 06250, United States

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Phase:

Phase 1

Estimated Enrollment:

12

Study ID:

NCT00891241

Recruitment Status:

Completed

Sponsor:


Lantheus Medical Imaging

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider